MELBOURNE, Australia — Shares of 4DMedical Ltd. (ASX: 4DX) exploded higher Wednesday, closing at A$6.23 after surging as much as 34.56% on record trading volume exceeding 30 million shares, as the medical imaging company announced more than US$100 million in new funding to accelerate its U.S. commercial rollout of revolutionary lung imaging software.

4DMedical Ltd
4DMedical Ltd

The Melbourne-based company, which develops non-invasive four-dimensional respiratory imaging technology, has seen its stock transform from a penny share trading around A$0.23 a year ago to a market darling now valued at roughly A$2.65 billion to A$3.58 billion depending on intraday calculations. Wednesday's move capped a stunning run in which the shares have gained more than 1,000% over the past 12 months, driven by regulatory wins, rapid clinical adoption and strategic capital raises.

4DMedical's flagship CT:VQ™ technology, which received U.S. Food and Drug Administration 510(k) clearance last year, provides quantitative ventilation and perfusion insights from standard CT scans without the need for radioactive tracers or contrast agents. Within just four months of clearance, the software was adopted by four elite U.S. academic medical centers: Stanford, Cleveland Clinic, University of Miami and UC San Diego Health. The latest funding round is expected to fuel broader commercial expansion, sales force growth and further technology development.

Trading opened at A$4.91 and quickly climbed, hitting an intraday high of A$6.47 before settling at A$6.23, up A$1.60 or 34.56% from Tuesday's close of A$4.63. Volume reached more than 30 million shares — far above the recent 10-day average — signaling intense investor interest amid positive momentum in the respiratory diagnostics sector.

The funding announcement, reported as exceeding US$100 million, comes on the heels of a A$150 million institutional placement completed in January that similarly boosted the company's cash position for U.S. commercialization. Proceeds are earmarked for scaling CT:VQ™ deployment, pursuing additional regulatory pathways and expanding partnerships, including an existing reseller agreement with Philips.

Chief Executive Andreas Fouras has described the period as one of "execution, validation and global momentum." The company's XV Technology™ platform uses advanced mathematical models and algorithms to convert sequences of X-ray or CT images into dynamic, quantitative four-dimensional data, offering clinicians functional lung information previously unavailable through traditional imaging.

Analysts have largely maintained bullish outlooks despite the rapid share price appreciation. Some firms have raised price targets to as high as A$4.90, though consensus figures from earlier in the quarter hovered around A$3.47 to A$4.20. Several brokers continue to rate the stock a speculative buy, citing the enormous addressable market in chronic respiratory diseases such as COPD, asthma and long COVID, where early and precise diagnosis remains challenging.

4DMedical reported strong half-year progress, including 31% growth in SaaS revenue and a 110% increase in scan volume. The company also secured Health Canada approval for CT:VQ™ late last year, broadening its international footprint. An ongoing U.S. clinical trial under an FDA Investigational Device Exemption is expected to generate additional data supporting reimbursement and wider adoption.

The stock's meteoric rise has not been without volatility. Earlier in March, shares traded in the A$3.70 to A$4.60 range before this week's breakout. Year-to-date gains now exceed 58%, while the one-year return stands at more than 1,800% compared with the S&P/ASX 200's modest advance. Beta of approximately 2.82 indicates the stock moves with amplified volatility relative to the broader market.

Investors appear drawn to 4DMedical's potential to disrupt a diagnostics market long dominated by nuclear medicine techniques that involve radiation exposure and logistical complexity. CT:VQ™ leverages existing hospital CT infrastructure, making it potentially more scalable and cost-effective. Reimbursement progress with the Centers for Medicare & Medicaid Services (CMS) has further de-risked the commercial pathway in the world's largest healthcare market.

Still, risks remain typical for a high-growth medtech firm. The company continues to report operating losses as it invests heavily in commercialization. Its latest half-year report carried a qualified audit review related to the valuation of intangible assets, a common feature among development-stage technology companies. Cash burn will require careful management even after recent capital injections.

Market watchers note that inclusion in the S&P/ASX All Ordinaries index during the March 2026 rebalance has likely increased visibility and passive fund buying. Expanded liquidity from the larger share register following placements and option exercises has also supported higher daily volumes.

4DMedical was founded to address limitations in respiratory diagnostics. Traditional ventilation-perfusion scans often require specialized equipment and expose patients to radiation. The company's software-based approach promises faster, safer and more quantitative results that could improve patient outcomes in conditions affecting hundreds of millions worldwide.

Partnerships with major players such as Philips are seen as critical for scaling. Under the agreement, 4DMedical's tools can be bundled with Philips CT systems, potentially accelerating placement in hospitals already using the manufacturer's equipment.

Looking ahead, analysts will watch for further U.S. customer wins, progress on the IDE trial and any updates on international expansion. Additional regulatory clearances in key markets could open new revenue streams. The company's fiscal year ends June 30, with the next full-year results expected to provide greater clarity on commercialization traction.

For retail investors, the stock's extraordinary run has prompted cautionary notes about valuation. At current levels, the market capitalization implies significant expectations for future revenue growth. Management has not provided formal guidance, but commentary points to accelerating adoption as more clinicians experience the technology's benefits.

Wednesday's surge occurred against a relatively flat broader Australian market, highlighting the stock-specific catalysts at play. Healthcare and technology sectors have attracted renewed interest amid global demand for innovative diagnostics, particularly post-pandemic awareness of respiratory health.

4DMedical employs about 124 people and maintains operations focused on research, software development and commercial activities. Its technology has roots in more than 15 years of preclinical and clinical studies, lending credibility to claims of scientific rigor.

As trading closed in Sydney, the bid-ask spread remained tight at A$6.22–A$6.24, reflecting strong liquidity despite the volatility. Short interest data was not immediately available, but the rapid price appreciation has occasionally drawn profit-taking in prior sessions.

The company's website and investor materials continue to emphasize its mission: "owning the lung" through superior functional imaging. Whether the stock can sustain its momentum will depend on execution in the competitive U.S. market and delivery of consistent commercial milestones.

For now, 4DMedical has captured the imagination of investors betting on the intersection of artificial intelligence, medical imaging and unmet clinical needs. Wednesday's dramatic session underscores how quickly sentiment can shift when tangible progress meets a receptive market.